---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-114435"
form_type: "8-K"
ticker: "EDSA"
cik: "0001540159"
company_name: "Edesa Biotech, Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T08:58:06.524609+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Edesa Biotech closes $3.0M private placement priced at $1.125 per share

## Summary
- Sold 2,691,337 common shares with warrants to purchase up to 1,345,665 shares each (12-month $1.00 and 3-year $1.50 exercise).
- Gross proceeds ~$3.0M; net proceeds for Phase 2b allergic contact dermatitis study, working capital and general corporate purposes.
- Officers and directors purchased $0.5 million of the securities in the offering.

## SEC filing metadata
- accession: 0001104659-22-114435
- form_type: 8-K
- ticker: EDSA
- cik: 0001540159
- company_name: Edesa Biotech, Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1540159/000110465922114435/0001104659-22-114435-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1540159/000110465922114435/tm2229551d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-114435
- JSON: https://secwatch.observer/filing/0001104659-22-114435.json
- Plain text: https://secwatch.observer/filing/0001104659-22-114435.txt

## Key facts
- Material Agreements
  Edesa Biotech, Inc. entered into Subscription Agreements with certain non-U.S. investors and certain United States resident investors valued at aggregate of 2,691,337 common shares, Class A Warrants for 1,345,665 shares, Class B Warrants for 1, (effective 2022-11-02).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain non-U.S. investors and certain United States resident investors
  - Value: aggregate of 2,691,337 common shares, Class A Warrants for 1,345,665 shares, Class B Warrants for 1,
  - Effective: 2022-11-02
  source text: On November 2, 2022, Edesa Biotech, Inc. (the “Company”) entered into Subscription Agreements with certain non-U.S. investors ( the “Non-U.S. Subscription Agreements”) and Subscription Agreements with certain United States resident investors (the “U.S. Subscription Agreements” and together with the Non-U.S. Subscription Agreements, the “Subscription Agreements”) providing for the issuance and sale by the Company of an aggregate of 2,691,337 (the “Shares”) of the Company’s common shares, no par value (the “Common Shares”), (ii) Class A Warrants to purchase up to an aggregate of 1,345,665 Common Shares (the “Class A Warrants”) and (iii) Class B Warrants to purchase up to an aggregate of 1,345,665 Common Shares (the “Class B Warrants”, and together with the Class A Warrants, the “Warrants”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1540159/000110465922114435/0001104659-22-114435-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.